Jerel Davis is a Director of Blueline Bioscience and an Investment Professional with Versant Ventures.Jerel joined Versant from McKinsey & Company where he was an Associate Principal. During his six years with McKinsey, he advised healthcare corporations in pharmaceuticals, biotechnology, medical device, and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia, and India. Jerel was a post doctoral researcher at Stanford University until 2005 and a researcher at Amgen from 1999-2000.Jerel is currently a board observer at Inception and Quanticel.Jerel received a PhD in Biological Sciences from Stanford University where he studied Genomics and Population Genetics. Jerel earned a BS in Biology and Mathematics from Pepperdine University.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Tentarix Biotherapeutics | Board of Directors | Aug 1, 2020 | — | Detail |
Versant Ventures | Managing Director | Apr 11, 2016 | — | Detail |